Loading...

We've got a brand new version of Simply Wall St! Try it out

MPX Bioceutical

CNSX:MPX
Snowflake Description

Limited growth with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MPX
CNSX
CA$478M
Market Cap
  1. Home
  2. CA
  3. Household
Company description

MPX Bioceutical Corporation, together with its subsidiaries, produces medical marijuana and pharma-grade products in North America. The last earnings update was 69 days ago. More info.


Add to Portfolio Compare Print
  • MPX Bioceutical has significant price volatility in the past 3 months.
MPX Share Price and Events
7 Day Returns
1.7%
CNSX:MPX
5.2%
CA Personal Products
1.3%
CA Market
1 Year Returns
68.6%
CNSX:MPX
-10.9%
CA Personal Products
-1.2%
CA Market
MPX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MPX Bioceutical (MPX) 1.7% 22.9% 12.4% 68.6% 1023.8% 2260%
CA Personal Products 5.2% 8.2% -6.1% -10.9% 381.6% 31.1%
CA Market 1.3% 7.7% 0.3% -1.2% 23.9% 6.5%
1 Year Return vs Industry and Market
  • MPX outperformed the Personal Products industry which returned -10.9% over the past year.
  • MPX outperformed the Market in Canada which returned -1.2% over the past year.
Price Volatility
MPX
Industry
5yr Volatility vs Market

MPX Value

 Is MPX Bioceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of MPX Bioceutical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for MPX Bioceutical.

CNSX:MPX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.3%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for CNSX:MPX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.9%
Equity Risk Premium S&P Global 8.1%
Personal Products Unlevered Beta Simply Wall St/ S&P Global 0.95
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.946 (1 + (1- 26.5%) (12.39%))
1.032
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.03
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (1.032 * 8.05%)
10.26%

Discounted Cash Flow Calculation for CNSX:MPX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for MPX Bioceutical is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

CNSX:MPX DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (CAD, Millions) -18.05 13.61 16.06 18.79 21.80
Source Analyst x1 Analyst x1 Est @ 18%, capped from 106.98% Est @ 17%, capped from 106.98% Est @ 16%, capped from 106.98%
Present Value
Discounted (@ 10.26%)
-16.37 11.20 11.98 12.72 13.38
Present value of next 5 years cash flows CA$32.90
CNSX:MPX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= CA$21.80 × (1 + 1.95%) ÷ (10.26% – 1.95%)
CA$267.45
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= CA$267.45 ÷ (1 + 10.26%)5
CA$164.14
CNSX:MPX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= CA$32.90 + CA$164.14
CA$197.05
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$197.05 / 404.95
CA$0.49
CNSX:MPX Discount to Share Price
Calculation Result
Value per share (CAD) From above. CA$0.49
Current discount Discount to share price of CA$1.18
= -1 x (CA$1.18 - CA$0.49) / CA$0.49
-142.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of MPX Bioceutical is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MPX Bioceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MPX Bioceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:MPX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in CAD CA$-0.13
CNSX:MPX Share Price ** CNSX (2019-02-05) in CAD CA$1.18
North America Personal Products Industry PE Ratio Median Figure of 20 Publicly-Listed Personal Products Companies 27.3x
Canada Market PE Ratio Median Figure of 559 Publicly-Listed Companies 14.33x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MPX Bioceutical.

CNSX:MPX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:MPX Share Price ÷ EPS (both in CAD)

= 1.18 ÷ -0.13

-9.2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MPX Bioceutical is loss making, we can't compare its value to the North America Personal Products industry average.
  • MPX Bioceutical is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does MPX Bioceutical's expected growth come at a high price?
Raw Data
CNSX:MPX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.2x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
North America Personal Products Industry PEG Ratio Median Figure of 9 Publicly-Listed Personal Products Companies 1.7x
Canada Market PEG Ratio Median Figure of 265 Publicly-Listed Companies 0.96x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MPX Bioceutical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MPX Bioceutical's assets?
Raw Data
CNSX:MPX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in CAD CA$0.20
CNSX:MPX Share Price * CNSX (2019-02-05) in CAD CA$1.18
Canada Personal Products Industry PB Ratio Median Figure of 17 Publicly-Listed Personal Products Companies 4.65x
Canada Market PB Ratio Median Figure of 2,317 Publicly-Listed Companies 1.52x
CNSX:MPX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:MPX Share Price ÷ Book Value per Share (both in CAD)

= 1.18 ÷ 0.20

5.94x

* Primary Listing of MPX Bioceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MPX Bioceutical is overvalued based on assets compared to the CA Personal Products industry average.
X
Value checks
We assess MPX Bioceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. MPX Bioceutical has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MPX Future Performance

 How is MPX Bioceutical expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
84.7%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is MPX Bioceutical expected to grow at an attractive rate?
  • Unable to compare MPX Bioceutical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare MPX Bioceutical's earnings growth to the Canada market average as no estimate data is available.
  • MPX Bioceutical's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:MPX Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:MPX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 84.7%
Canada Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 67.5%
Canada Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 36.3%
Canada Market Earnings Growth Rate Market Cap Weighted Average 15.5%
Canada Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:MPX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:MPX Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-03-31 205 1
2019-03-31 124 1
CNSX:MPX Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-09-30 42 -12 -45
2018-06-30 31 -9 -29
2018-03-31 21 -7 -17
2017-12-31 18 -5 -16
2017-09-30 13 -5 -8
2017-06-30 9 -4 -6
2017-03-31 4 -1 -5
2016-12-31 0 -0 -3
2016-09-30 0 -0 -3
2016-06-30 0 -1 -3
2016-03-31 0 -1 -3
2015-12-31 0 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if MPX Bioceutical is high growth as no earnings estimate data is available.
  • MPX Bioceutical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:MPX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from MPX Bioceutical Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:MPX Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-03-31
2019-03-31
CNSX:MPX Past Financials Data
Date (Data in CAD Millions) EPS *
2018-09-30 -0.13
2018-06-30 -0.09
2018-03-31 -0.06
2017-12-31 -0.07
2017-09-30 -0.04
2017-06-30 -0.04
2017-03-31 -0.07
2016-12-31 -0.07
2016-09-30 -0.07
2016-06-30 -0.07
2016-03-31 -0.07
2015-12-31 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MPX Bioceutical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess MPX Bioceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MPX Bioceutical has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MPX Past Performance

  How has MPX Bioceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MPX Bioceutical's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MPX Bioceutical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare MPX Bioceutical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MPX Bioceutical's 1-year growth to the North America Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
MPX Bioceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MPX Bioceutical Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:MPX Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 41.60 -44.60 33.20
2018-06-30 31.33 -29.14 25.26
2018-03-31 21.33 -17.44 18.70
2017-12-31 17.74 -16.24 15.23
2017-09-30 13.26 -7.56 10.94
2017-06-30 8.85 -5.88 7.88
2017-03-31 4.38 -5.23 5.38
2016-12-31 0.00 -3.23 1.80
2016-09-30 0.00 -2.93 1.54
2016-06-30 0.00 -2.99 1.56
2016-03-31 0.01 -2.90 1.56
2015-12-31 0.01 -1.14 1.06
2015-09-30 0.01 -1.26 1.13
2015-06-30 0.01 -0.98 0.84
2015-03-31 0.01 -0.73 0.60
2014-12-31 0.00 -0.41 0.23
2014-09-30 -0.06 0.07
2014-06-30 -0.04 0.08
2014-03-31 -0.03 0.06
2013-12-31 -0.09 0.12
2013-09-30 -0.10 0.16
2013-06-30 -0.26 0.30
2013-03-31 -0.30 0.39
2012-12-31 0.00 -0.29 0.39 0.01
2012-09-30 0.00 -0.27 0.36 0.01
2012-06-30 0.00 -0.56 0.70 0.01
2012-03-31 0.02 -0.53 0.67 0.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MPX Bioceutical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if MPX Bioceutical has efficiently used its assets last year compared to the North America Personal Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MPX Bioceutical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MPX Bioceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MPX Bioceutical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MPX Health

 How is MPX Bioceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MPX Bioceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MPX Bioceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MPX Bioceutical's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of MPX Bioceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MPX Bioceutical Company Filings, last reported 4 months ago.

CNSX:MPX Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 83.07 59.22 17.67
2018-06-30 99.80 57.93 30.69
2018-03-31 82.03 35.42 8.50
2017-12-31 71.06 33.54 32.31
2017-09-30 45.85 13.90 4.78
2017-06-30 49.72 14.46 10.26
2017-03-31 42.14 14.85 21.52
2016-12-31 -1.98 0.16 0.04
2016-09-30 -1.42 0.13 0.03
2016-06-30 -1.19 0.09 0.04
2016-03-31 -0.84 0.02 0.03
2015-12-31 1.24 0.02 0.04
2015-09-30 1.42 0.00 0.10
2015-06-30 1.53 0.00 0.26
2015-03-31 1.48 0.00 0.33
2014-12-31 0.96 0.64 0.67
2014-09-30 -0.32 0.19 0.00
2014-06-30 -0.29 0.19 0.02
2014-03-31 -0.27 0.19 0.02
2013-12-31 -0.31 0.19 0.02
2013-09-30 -0.28 0.19 0.03
2013-06-30 -0.29 0.19 0.04
2013-03-31 -0.28 0.19 0.07
2012-12-31 -0.33 0.22 0.05
2012-09-30 -0.27 0.19 0.07
2012-06-30 -0.27 0.23 0.10
2012-03-31 -0.17 0.19 0.13
  • MPX Bioceutical's level of debt (71.3%) compared to net worth is high (greater than 40%).
  • MPX Bioceutical had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MPX Bioceutical has less than a year of cash runway based on current free cash flow.
  • MPX Bioceutical has less than a year of cash runway if free cash flow continues to grow at historical rates of 108.5% each year.
X
Financial health checks
We assess MPX Bioceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MPX Bioceutical has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MPX Dividends

 What is MPX Bioceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MPX Bioceutical dividends.
If you bought CA$2,000 of MPX Bioceutical shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MPX Bioceutical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MPX Bioceutical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:MPX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
North America Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.9%
Canada Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.6%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2.2%
Canada Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:MPX Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2020-03-31
2019-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MPX Bioceutical has not reported any payouts.
  • Unable to verify if MPX Bioceutical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MPX Bioceutical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MPX Bioceutical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MPX Bioceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MPX Bioceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MPX Bioceutical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MPX Management

 What is the CEO of MPX Bioceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
W. Boyes
COMPENSATION CA$174,394
AGE 68
TENURE AS CEO 4.1 years
CEO Bio

Mr. W. Scott Boyes, BA, MBA, has served as the Chairman since October 30, 2017, President and Chief Executive Officer since November 24, 2014 at MPX Bioceutical Corporation. He has been the Chief Executive Officer and President of The Canadian Bioceutical Corporation since January 2015 and November 18, 2014 respectively and Director since November 18, 2014. Mr. Boyes serves as the Chairman of The Canadian Bioceutical Corporation. He is an Independent Businessman and has 40+ years experience.

CEO Compensation
  • W.'s compensation has increased whilst company is loss making.
  • W.'s remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the MPX Bioceutical management team in years:

2.2
Average Tenure
48
Average Age
  • The tenure for the MPX Bioceutical management team is about average.
Management Team

W. Boyes

TITLE
Chairman
COMPENSATION
CA$174K
AGE
68
TENURE
4.1 yrs

Beth Stavola

TITLE
Chief Operating Officer

David McLaren

TITLE
Chief Financial Officer
AGE
48
TENURE
1.1 yrs

Jonathan Chu

TITLE
Vice President of Accounting
TENURE
2.2 yrs

Jeremy Budd

TITLE
VP, General Counsel
AGE
40

Michael Arnkvarn

TITLE
Executive Vice President of Sales & Marketing
Board of Directors Tenure

Average tenure and age of the MPX Bioceutical board of directors in years:

1.3
Average Tenure
62.5
Average Age
  • The average tenure for the MPX Bioceutical board of directors is less than 3 years, this suggests a new board.
Board of Directors

Beth Stavola

TITLE
Chief Operating Officer
TENURE
1.3 yrs

Jeremy Budd

TITLE
VP, General Counsel
AGE
40
TENURE
0.3 yrs

Randy Stafford

TITLE
Director
COMPENSATION
CA$31K
TENURE
4.3 yrs

W. Boyes

TITLE
Chairman
COMPENSATION
CA$174K
AGE
68
TENURE
1.3 yrs

Bob Galvin

TITLE
Director
AGE
57
TENURE
1.3 yrs

Andrew Ryan

TITLE
Director
TENURE
1.3 yrs

Trick Segerblom

TITLE
Director
AGE
70
TENURE
1.3 yrs

Miles Thompson

TITLE
Director
TENURE
1.3 yrs

Robert Petch

TITLE
Director
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by MPX Bioceutical insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
09. Jan 19 Buy Randall Stafford Individual 04. Jan 19 04. Jan 19 12,500 CA$0.95 CA$11,875
30. Nov 18 Buy Hi-Med, LLC Company 05. May 17 05. May 17 239,904 CA$0.50 CA$119,952
01. Mar 18 Buy Andrew Ryan Individual 13. Feb 18 13. Feb 18 230,000 CA$0.35 CA$80,500
01. Mar 18 Buy Robert Galvin Individual 13. Feb 18 13. Feb 18 230,000 CA$0.35 CA$80,500
X
Management checks
We assess MPX Bioceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MPX Bioceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MPX News

Simply Wall St News

Are MPX Bioceutical Corporation's (CNSX:MPX) Interest Costs Too High?

Investors are always looking for growth in small-cap stocks like MPX Bioceutical Corporation (CNSX:MPX), with a market cap of CA$397.49m. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

MPX Company Info

Map
Description

MPX Bioceutical Corporation, together with its subsidiaries, produces medical marijuana and pharma-grade products in North America. The company engages in the cultivation, manufacture, production, use, sale, or distribution of cannabis in the Arizona medical marijuana market, and the medical and adult-use market. It also provides management, staffing, procurement, advisory, financial, real estate rental, logistics, and administrative services to medicinal cannabis enterprises; and nutraceuticals. The company was formerly known as The Canadian Bioceutical Corporation and changed its name to MPX Bioceutical Corporation in November 2017. MPX Bioceutical Corporation was incorporated in 1974 and is based in Toronto, Canada.

Details
Name: MPX Bioceutical Corporation
MPX
Exchange: CNSX
Founded: 1974
CA$477,845,767
404,954,040
Website: http://www.mpxbioceutical.com
Address: MPX Bioceutical Corporation
5255 Yonge Street,
Suite 701,
Toronto,
Ontario, M2N 6P4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX MPX Common Shares Canadian National Stock Exchange CA CAD 19. Sep 1988
DB 5CB Common Shares Deutsche Boerse AG DE EUR 19. Sep 1988
Number of employees
Current staff
Staff numbers
0
MPX Bioceutical employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/06 00:43
End of day share price update: 2019/02/05 00:00
Last estimates confirmation: 2018/10/12
Last earnings filing: 2018/11/29
Last earnings reported: 2018/09/30
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.